Skip to main
HUM
HUM logo

Humana (HUM) Stock Forecast & Price Target

Humana (HUM) Analyst Ratings

Based on 17 analyst ratings
Hold
Strong Buy 12%
Buy 29%
Hold 59%
Sell 0%
Strong Sell 0%

Bulls say

Humana's strong financial outlook is underscored by the upward revision of its 2025 earnings per share (EPS) estimate to $17.06, reflecting positive second-quarter results and adjusted guidance. The company anticipates year-over-year earnings growth for 2027, driven by effective margin initiatives, highlighting its ability to navigate the competitive landscape in government-sponsored healthcare programs. Additionally, Humana's strong performance in Medicare Advantage star ratings strengthens its market position, providing a competitive advantage amidst changing regulatory and reimbursement environments.

Bears say

Humana is facing a challenging outlook with expectations of a slight decline in earnings per share (EPS) for 2026 compared to 2025, primarily influenced by headwinds related to the Medicare Star ratings. Key downside risks include increased competition in Medicare Advantage (MA), lower reimbursement rates, and a decrease in individual prescription drug plan (PDP) membership, all potentially impacting overall growth in healthcare services. Additionally, the management acknowledges that increased investments may be necessary to support the recovery of Star ratings, which could further strain future earnings projections.

Humana (HUM) has been analyzed by 17 analysts, with a consensus rating of Hold. 12% of analysts recommend a Strong Buy, 29% recommend Buy, 59% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Humana and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Humana (HUM) Forecast

Analysts have given Humana (HUM) a Hold based on their latest research and market trends.

According to 17 analysts, Humana (HUM) has a Hold consensus rating as of Dec 11, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $299.53, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $299.53, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Humana (HUM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.